Read More Pharma Industry News Thryv Therapeutics secures FDA IND clearance to launch first potential drug for Long QT syndrome Thryv Therapeutics gains FDA IND clearance for THRV-1268 in Long QT Syndrome, aiming to pioneer the first disease-modifying therapy for this rare disorder. bySoujanya RaviSeptember 18, 2025